SMC Accepts First Drug to Improve Survival in Uveal Melanoma

Published Date: 15 Jul 2026

Scotland approves tebentafusp for metastatic uveal melanoma, a rare eye cancer with a median survival of around 12 months.

Read Full News

Latest News

Prostate Cancer Spending Nearly Quadrupled Over 10 Years

Medicare spending on prostate cancer care rose sharply from 2012 to 2021, driven largely by increased spending on systemic therapies.

Do IL-17 Inhibitors Increase IBD Risk in HS?

A meta-analysis finds no significant increase in the risk for inflammatory bowel disease among patients with hidradenitis suppurativa treated with IL-17 inhibitors.

Adjuvant Anti-PD-1 Boosts OS in Matched Melanoma Cases

Adjuvant anti-PD-1 therapy is tied to higher 5-year overall survival in patients with stage III melanoma in a matched analysis, but the population-level benefit remains unproven, a Danish study finds.

Kennedy Acknowledges One Measles Death in Pennsylvania

U.S. Health Secretary Robert F. Kennedy Jr acknowledged on Friday that measles caused the recent death of an infant in Pennsylvania, citing information from a county...

Do Pilots, Flight Crew Have Higher Cancer Mortality Risk?

Aircrew may be more likely to die from cancers potentially linked to radiation, but can that be attributed to cosmic radiation — and what, if anything, should physicians do differently?

Sunscreen, Collagen: Do Viral Social Media Claims Hold Up?

Viral discussions about sun protection, vitamin D, and oral collagen often outpace the evidence, leaving clinicians to weigh the benefits, limitations, and patient concerns.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Latest News

Medicare spending on prostate cancer care rose sharply from 2012 to 2021, driven largely by increased spending on systemic therapies.

A meta-analysis finds no significant increase in the risk for inflammatory bowel disease among patients with hidradenitis suppurativa treated with IL-17 inhibitors.

Adjuvant anti-PD-1 therapy is tied to higher 5-year overall survival in patients with stage III melanoma in a matched analysis, but the population-level benefit remains unproven, a Danish study finds.

U.S. Health Secretary Robert F. Kennedy Jr acknowledged on Friday that measles caused the recent death of an infant in Pennsylvania, citing information from a county...

Aircrew may be more likely to die from cancers potentially linked to radiation, but can that be attributed to cosmic radiation — and what, if anything, should physicians do differently?

Viral discussions about sun protection, vitamin D, and oral collagen often outpace the evidence, leaving clinicians to weigh the benefits, limitations, and patient concerns.

News All Time

Experts Say One Menopause Treatment Cannot Fit Every Woman

Experts emphasise individualised menopause care, with treatment decisions guided by symptoms, health risks, preferences, and changing needs rather than a fixed approach.

Sleepmaxxing: Are Popular Sleep Hacks Evidence-Based?

Sleepmaxxing practices vary in their evidence, with some routines supported by research, while others lack proven benefits or may worsen sleep problems.

Vitamin D Deficiency Needs a Tailored Approach

Vitamin D deficiency may improve in summer, but experts say many patients still need individualized treatment, especially if sun exposure is limited.

Diclofenac Did Not Reduce Chemo-Induced Hand-Foot Syndrome

Researchers assess hand-foot syndrome in patients receiving diclofenac who are scheduled to receive capecitabine-based chemotherapy for cancer.

Upadacitinib Effective in PsA After TNF Inhibitor Failure

Upadacitinib is linked to effective clinical responses in patients with psoriatic arthritis who have received prior TNF inhibitor therapy.

Does Tapering TNF Inhibitors Maintain Low Disease Activity?

In patients with psoriatic arthritis and axial spondyloarthritis, a treat-to-target tapering strategy for TNF inhibitors may maintain low disease activity for up to 2 years.

FDA Approves First Oral Drug for Dermatomyositis in Adults

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

Early Step-Down Safe, Cost-Effective in Stable Candidiasis

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

China Approves J&J Psoriasis Pill Icotyde, Says Drugmaker

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar Lichen Sclerosus Affects 1 in 700 US Women

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib Controls Skin Disease in Dermatomyositis

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

ctDNA Detects Postsurgical Merkel Cell Recurrence

Circulating tumor DNA surveillance detects Merkel cell carcinoma recurrence after curative-intent surgery.

Biologic Choice May Affect PsA Progression in Psoriasis

In patients with psoriasis, interleukin-targeting inhibitors are associated with a lower risk for psoriatic arthritis than TNF inhibitors, a long-term real-world study finds.

Longer Targeted Therapy May Not Raise Cancer Risk in SpA

Using targeted therapy for spondyloarthritis for more than 6 months per year is not associated with an increased risk for cancer compared with using targeted therapy for shorter durations.

Ruxolitinib Improves Vitiligo Outcomes in Real-World Study

Topical ruxolitinib shows sustained repigmentation through 52 weeks with improvements in anxiety and depression in patients with non-segmental vitiligo.

Recommended News For You

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

Combination therapy improves outcomes for advanced triple-negative breast cancer

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?

An Intimate Life of Medical Innovation and Charity.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

Recommended Articles For You

Rehabilitation of Hand Dexterity Following Hematologic Treatment-Associated Deconditioning 

Bone-on-a-Chip Systems: A Revolutionary Approach to Modeling Hematological Cancers 

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice 

From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women

1.

Tumor Ecosystem Rewiring Through Adaptive Therapeutics

2.

Seeing the Unseen: Examining Chancroid Through Images

3.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

4.

The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology

5.

Decoding Granular Cell Tumor: What You Need to Know

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Advances in Modern Cancer Treatment

2.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

3.

Thromboprophylaxis In Medical Settings

4.

Navigating the Complexities of Ph Negative ALL - Part VII

5.

Managing Common Side Effects During Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot